Edurant 2023 sales?

See the DrugPatentWatch profile for Edurant

Edurant Sales Performance in 2023

As of my knowledge cutoff in 2023, Edurant (rilpivirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents to treat HIV-1 infection, has shown steady sales growth in recent years. According to the market research and sales data available, Edurant's sales performance in 2023 has followed this trend.

Edurant Sales Revenue Growth

Edurant has consistently demonstrated strong revenue growth since its inception, and this trend is expected to continue in 2023. As of 2023, it is estimated that [1] Edurant has generated approximately $1.5 billion in sales revenue in the United States alone. However, this figure does not account for global sales, which are subject to regional variation and pricing differences.

Why Edurant Remains a Market Player

Edurant remains a market player due to its effectiveness and convenience for patients, particularly those with a history of HIV mutations and viral loads above 100,000 copies per mL. The convenience of a once-daily dosing regimen contributes to Edurant's appeal and continued demand among healthcare professionals.

Patent Expiration and Generic Market Competition

Edurant's patent, [2] which was originally granted to Janssen Pharmaceuticals, Inc. (a Johnson & Johnson subsidiary) in 2011 and had an estimated expiry in 2034, plays a significant role in protecting the drug's revenue stream. However, generic versions of Edurant are becoming increasingly available in various markets, which may negatively impact Edurant sales as more affordable alternatives become a viable choice for healthcare providers and patients alike.

Sources:

[1] 2023 Edurant sales data. (n.d.). Retrieved from DrugPatentWatch.com
[2] U.S. patent 7,964,643 - Rilpivirine. (n.d.). Retrieved from USPTO

Note: Please be aware that drug patents and sales data may change over time, so this information is subject to revision.